



Topical ocular drug delivery for glaucoma, myopia and other eye diseases. Can be worn without replacement for months providing constant 24/7, controlled drug delivery. Solves eye drop failings including dosing variability, avoidable side-effects, instillation difficulties and high rates of non-compliance.

### Overview

Amorphex Therapeutics has developed a novel, patented Topical Ophthalmic Drug Delivery Device -**TODDD™**, a soft, flexible device that floats on the tear film completely concealed under the eyelid. It is easily and quickly replaced by practice staff or even the patient themselves. Animal testing and preliminary human trials have confirmed safety and efficacy.

### Technology

**TODDD™** is a non-invasive biocompatible elastomeric device that is placed on the white scleral surface of the eye and concealed completely under the eyelid.

- Continuously delivers micro-doses of therapeutic 24/7
- Exceptionally large capacity for delivery of medication over several months
- Design optimized for comfort, ease of insertion, long term retention and ease of removal
- Drug can be polymerized into a customized material matrix or loaded into one or multiple specially designed drug depots
- Capable of delivering several drugs simultaneously and at different rates
- Patents issued in US, Canada, Europe & Japan



TODDD™ with highlighted drug depots. Its matrix body can also carry a 3<sup>rd</sup> API.

### Addressable Market – Competitive Advantages

- Ophthalmic topical drug delivery for glaucoma, dry eye, allergies, infection & inflammation - \$5+ Billion annually.
- Numerous comparative advantages over eye drops and competitive alternatives
- The TODDD technology provides much more reliable drug delivery for multiple drugs over longer periods of time resulting in:
  - Easier and more effective therapy for patients
  - Easy to adopt, improved disease management for physicians
  - Reduced total patient care costs for care providers and insurers
  - Distinct competitive advantages for pharma companies including extending the effective patent life of their proprietary drugs

### Management Team

#### CEO

##### Robert Thompson

- Extensive start-up and development experience
- Former president of 2 Bausch & Lomb divisions

#### VP of Technology

##### Edward Ellis, PhD

- 30+ patents with more than \$2 billion in sales

#### VP of Clinical Affairs

##### Charles Leahy, OD, MS

- Practicing clinician - Massachusetts Eye & Ear Infirmary/Harvard Medical School


#### Legal Counsel

Morse, Barnes-Brown & Pendleton

Leason-Ellis

#### Accounting Firm

Brady and Company P.C.



### Contact Us

#### Robert Thompson Amorphex Therapeutics

1 Dundee Park, Suite 8  
Andover, MA 01810,  
USA  
(781) 891-9351

[rftom@gmail.com](mailto:rftom@gmail.com)

[www.amorphexusa.com](http://www.amorphexusa.com)

## Technology Development Milestones

- Completed 3rd NIH SBIR grant (Phase II-a), \$2.5 million total
- Demonstrated uninterrupted therapeutic efficacy in human for 180 days
- Demonstrated efficacy in 90 day timolol rabbit study
- Reduced IOP more than 35% in a prostaglandin beagle study
- Demonstrated safety, comfort and retention in human clinical trials
- Developed low cost pilot cast molding manufacturing process
- Patents in major markets / No freedom to operate issues identified

## Next Steps – Technology

Amorphex will conduct human therapeutic clinical trials of TODDD™ (30+/- subjects) delivering timolol, prostaglandin and both drugs simultaneously. This funding will also support pre-clinical development and a clinical trial of TODDD™ for managing myopia progression.

## Business Model

Amorphex’s revenue model is based on product licensing agreements or acquisition. With the completion of this proposed round of human trials, the TODDD™ technology will be sufficiently developed and its safety and efficacy demonstrated such that ophthalmic drug companies will be prime potential partners. There are more than 10 unique drug and multiple drug delivery combinations with substantial annual revenues that could utilize TODDD™ technology.

We expect to enter into several licensing agreements that would provide upfront, milestone and royalty payments. A major portion of this cash would be used for investor distribution, with the remainder funding further product development for additional licensing opportunities.

## Funding Sought

Amorphex Therapeutics has received over \$4 million of funding to date of which \$2.5 million was NIH grants. We are seeking an additional \$7.6 million of funding in two tiers. These funds will be deployed over 3 years and follow a clear path to several substantial increases in valuation.

## Advisory Board

### L. Jay Katz, MD

- Director of Glaucoma Service, Wills Eye Hosp.

### Martin Wax, MD

- CMO, Pan Optica, Inc.

### Thomas Brunner, MBA

- President of Glaucoma Research Foundation

### Thomas Capetan, MBA

- Former VP of Licensing, Alcon Labs

### David Marsh, PhD

- Former Research Investigator, Drug Delivery, Allergan

## TODDD™ PLATFORM Product Pipeline

TODDD Product	Disease Addressed	Year 1	Year 2	Year 3	Market Size
<i>timolol</i>	Glaucoma (mild to moderate)	90-day Human Safety and Feasibility Clinical			\$2+b
<i>prostaglandin</i>	Glaucoma (mild to moderate)	Pre-Clinical, 90-day Human Safety and Feasibility Clinical			\$2+b
<i>prostaglandin + timolol</i>	Glaucoma (moderate)	Pre-Clinical, 90-day Human Safety and Feasibility Clinical			\$2+b
<i>myopia treatment</i>	Myopia Progression	Pre-Clinical, 1-year Human Safety and Feasibility Clinical			\$++b
<i>olopatadine</i>	Ocular Allergies		Formulation, Drug Release	Pre-Clinical Safety and Analysis	\$1+b